Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

CPG 10101 Combination Therapy for the Treatment of Hepatitis C

Study:

CPG 10101 Combination Therapy for the Treatment of Hepatitis C: A Phase IB Open Label Randomized Trial of CPG 10101 Alone, With Interferon, Ribavirin, or Interferon and Ribavirin in the Treatment of Relapsed HCV Subjects

Rationale:

n/a

Purpose:

- To characterize the tolerability profile of subcutaneous (SC) CPG 10101 alone, with pegylated interferon, ribavirin or both pegylated interferon and ribavirin when administered weekly for twelve weeks in relapsed HCV positive subjects. - To assess the effect of subcutaneous (SC) CPG 10101 alone, with pegylated interferon, ribavirin or both pegylated interferon and ribavirin on serum Hepatitis C Virus (HCV) RNA concentrations

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Hepatitis C Virus Drug: CPG 10101
Drug: Ribavirin
Drug: Pegylated Interferon
Phase 1

Verified by Pfizer May, 2008

Sponsored by: Pfizer
Information provided by: Pfizer
ClinicalTrials.gov identifier: NCT00142103

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site